Bitcoin (BTC) remained above $80,000, trading at $82,315 on Oct. 19, after recent price rebounds stalled near the $84,000 resistance. The $80,000 level acts as a key pivot within an ascending channel that started from lows near $58,000 in late June. BTC has faced resistance near $88,000 twice since late September, and a sustained move above $84,000 could renew focus on the $86,000-$88,000 range. Conversely, a daily close below $80,000 might target support near $77,000, with further downside possible near $75,000 if the price breaks below key trendlines. The 30-day adjusted Spent Output Profit Ratio indicates some profit-taking but does not clarify the next market direction.
Bitcoin held above $80,000 as of Oct 20, 2026 06:02 WIB, providing context for recent price movements near $84,000. For readers following major cryptocurrencies on Pluang, 42 of 50 rose today. Notable movers include SAND at Rp1.067 with a 1-day change of +2.90%, BCH at Rp5.026.924 with +2.84%, and GRT at Rp429 with +2.74%.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
